Retatrutide Phase 3 Data: Summary for Research Laboratories

For laboratory research use only.

Retatrutide, a triple receptor agonist, is generating significant interest in metabolic research. This article summarizes public data from Phase 3 trial registries.

Triple Receptor Pharmacology

Retatrutide simultaneously activates GIP, GLP-1, and glucagon receptors. This triple agonism is being studied in detail for its impact on energy expenditure and lipolysis in adipocyte and hepatocyte models.

Metabolic Models

In-vitro studies with human adipose tissue explants show pronounced effects on lipolysis and mitochondrial biogenesis, differing from dual agonists.

Trial Registries

Data from public registries provide researchers with valuable pharmacokinetic parameters for designing more precise in-vitro experiments.

For laboratory research use only.

→ Retatrutide Research Grade Peptide
→ Retatrutide vs Tirzepatide
→ Weight Loss Research Peptides

Author: Dr. Elena Voss, PhD Biochemistry – Senior Researcher, PenLab Peptide Research Division

Article 47 (Week 23 – EN)